Patents by Inventor Robin Farias-Eisner
Robin Farias-Eisner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10208103Abstract: Molecules and compositions are described for use in the treatment and prevention of pro-inflammatory conditions. HDL-related molecules, including ApoA-I, bovine HDL and HDL mimetics, in particular, are demonstrated to prevent UV-induced cell death and oxidative stress in skin cells and to inhibit tumor growth and development in a variety of cancers. HDL-related molecules can be used as an oral supplement and in other compositions to prevent or treat pro-inflammatory skin conditions and systemic proinflammatory conditions, including Alzheimer's disease and various cancers.Type: GrantFiled: January 22, 2016Date of Patent: February 19, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Publication number: 20170204160Abstract: Molecules and compositions are described for use in the treatment and prevention of proinflammatory conditions. HDL-related molecules, including ApoA-I, bovine HDL and HDL mimetics, in particular, are demonstrated to prevent UV-induced cell death and oxidative stress in skin cells and to inhibit tumor growth and development in a variety of cancers. HDL-related molecules can be used as an oral supplement and in other compositions to prevent or treat proinflammatory skin conditions and systemic proinflammatory conditions, including Alzheimer's disease and various cancers.Type: ApplicationFiled: January 22, 2016Publication date: July 20, 2017Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Patent number: 9488655Abstract: Biomarker proteins that can be used in the diagnosis of early-stage endometrial cancer are described. Methods of screening for endometrial cancer, as well as methods of detecting and monitoring the status of endometrial cancer are provided. The biomarkers can be used to detect a variety of endometrial cancers, including endometroid carcinoma, clear cell carcinoma and serous carcinoma.Type: GrantFiled: August 20, 2010Date of Patent: November 8, 2016Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Patent number: 9487575Abstract: Molecules and compositions that can be used in the treatment of gynecologic cancers are described. ApoA-1, in particular, is demonstrated to inhibit the proliferation of cancer cells reduce tumor size in a mouse model of ovarian cancer.Type: GrantFiled: October 4, 2011Date of Patent: November 8, 2016Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Publication number: 20160069886Abstract: Biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules.Type: ApplicationFiled: August 17, 2015Publication date: March 10, 2016Inventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Patent number: 9241976Abstract: Molecules and compositions are described for use in the treatment and prevention of pro-inflammatory conditions. HDL-related molecules, including ApoA-I, bovine HDL and HDL mimetics, in particular, are demonstrated to prevent UV-induced cell death and oxidative stress in skin cells and to inhibit tumor growth and development in a variety of cancers. HDL-related molecules can be used as an oral supplement and in other compositions to prevent or treat pro-inflammatory skin conditions and systemic proinflammatory conditions, including Alzheimer's disease and various cancers.Type: GrantFiled: August 29, 2012Date of Patent: January 26, 2016Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Patent number: 9110083Abstract: Biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules.Type: GrantFiled: November 28, 2012Date of Patent: August 18, 2015Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Publication number: 20140323410Abstract: Molecules and compositions are described for use in the treatment and prevention of pro-inflammatory conditions. HDL-related molecules, including ApoA-I, bovine HDL and HDL mimetics, in particular, are demonstrated to prevent UV-induced cell death and oxidative stress in skin cells and to inhibit tumor growth and development in a variety of cancers. HDL-related molecules can be used as an oral supplement and in other compositions to prevent or treat pro-inflammatory skin conditions and systemic proinflammatory conditions, including Alzheimer's disease and various cancers.Type: ApplicationFiled: August 29, 2012Publication date: October 30, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Publication number: 20140088018Abstract: Molecules and compositions that can be used in the treatment of gynecologic cancers are described. ApoA-1, in particular, is demonstrated to inhibit the proliferation of cancer cells reduce tumor size in a mouse model of ovarian cancer.Type: ApplicationFiled: October 4, 2011Publication date: March 27, 2014Applicant: The Regents of the University of CaliforniaInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Publication number: 20130217636Abstract: Molecules and compositions that can be used in the treatment of gynecologic cancers are described. ApoA-1, in particular, is demonstrated to inhibit the proliferation of cancer cells reduce tumor size in a mouse model of ovarian cancer.Type: ApplicationFiled: October 4, 2011Publication date: August 22, 2013Applicant: The Regents of the University of CaliforniaInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Patent number: 8323915Abstract: Biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules.Type: GrantFiled: December 3, 2009Date of Patent: December 4, 2012Assignee: The Regents of the University of CaliforniaInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Publication number: 20110027894Abstract: Biomarker proteins that can be used in the diagnosis of early-stage endometrial cancer are described. Methods of screening for endometrial cancer, as well as methods of detecting and monitoring the status of endometrial cancer are provided. The biomarkers can be used to detect a variety of endometrial cancers, including endometroid carcinoma, clear cell carcinoma and serous carcinoma.Type: ApplicationFiled: August 20, 2010Publication date: February 3, 2011Applicant: The Regents of the University of CaliforniaInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Publication number: 20100081151Abstract: Biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules.Type: ApplicationFiled: December 3, 2009Publication date: April 1, 2010Applicant: The Regents of the University of CaliforniaInventors: ROBIN FARIAS-EISNER, Srinivasa T. Reddy
-
Patent number: 7670792Abstract: Biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules.Type: GrantFiled: July 14, 2005Date of Patent: March 2, 2010Assignee: The Regents of the University of CaliforniaInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Publication number: 20080038754Abstract: Three panels of biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules.Type: ApplicationFiled: July 14, 2005Publication date: February 14, 2008Applicant: The Regents of the University of CaliforniaInventors: Robin Farias-Eisner, Srinivasa Reddy